An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
Ritter
M A
MA
Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA.
Furtek
C I
CI
Lo
M W
MW
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000032:analysis* / Q000097:blood / Q000652:urine; D001713:Biphenyl Compounds / Q000032:analysis* / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007093:Imidazoles / Q000032:analysis* / Q000097:blood / Q000652:urine; D019808:Losartan; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence; D013777:Tetrazoles / Q000032:analysis* / Q000097:blood / Q000652:urine
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; C066026:losartan carboxylic acid; D019808:Losartan